{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Humulin+L&page=2",
    "query": {
      "intervention": "Humulin L",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Humulin+L&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T06:19:07.015Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02585778",
      "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lipid-Modifying Therapy (LMT)",
          "type": "DRUG"
        },
        {
          "name": "Antihyperglycemic Drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2015-10-23",
      "completion_date": "2017-04-03",
      "has_results": true,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 29,
      "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585778"
    },
    {
      "nct_id": "NCT00795704",
      "title": "Impact of Mulberry Leaf on Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Mulberry Leaf Extract",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2008-04",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-08-09",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00795704"
    },
    {
      "nct_id": "NCT06624956",
      "title": "Prevention and Treatment of Common Hyperglycemia in Surgery Pilot",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Surgery",
        "Non Diabetic Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "glucose, insulin, and potassium (GIK)",
          "type": "DRUG"
        },
        {
          "name": "Crystalloid Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2024-09-04",
      "completion_date": "2026-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06624956"
    },
    {
      "nct_id": "NCT04673656",
      "title": "Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "BKR-017",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "BioKier Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-04-18",
      "completion_date": "2023-02-07",
      "has_results": false,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 3,
      "location_summary": "Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Kannapolis",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04673656"
    },
    {
      "nct_id": "NCT01476475",
      "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine /lixisenatide Fixed Ratio Combination",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Metformin (Background drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2011-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Larenceville",
          "state": "Georgia"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01476475"
    },
    {
      "nct_id": "NCT03751657",
      "title": "A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin icodec",
          "type": "DRUG"
        },
        {
          "name": "Placebo (insulin 287)",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl peptidase-4 inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Placebo (insulin glargine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 247,
      "start_date": "2018-11-29",
      "completion_date": "2020-01-17",
      "has_results": true,
      "last_update_posted_date": "2021-04-02",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 14,
      "location_summary": "Lancaster, California • Ventura, California • Walnut Creek, California + 9 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03751657"
    },
    {
      "nct_id": "NCT04939792",
      "title": "Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "Vitamin D",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D + L-cysteine",
          "type": "DRUG"
        },
        {
          "name": "L-cysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center Shreveport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 165,
      "start_date": "2020-11-06",
      "completion_date": "2022-10-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04939792"
    },
    {
      "nct_id": "NCT01187329",
      "title": "The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperglycemia",
        "Aortic Valve Replacement",
        "Aortic Stenosis",
        "Cardiac Surgery"
      ],
      "interventions": [
        {
          "name": "hyperinsulinemic normoglycemic clamp (HNC)",
          "type": "OTHER"
        },
        {
          "name": "control group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "40 Years to 84 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01187329"
    },
    {
      "nct_id": "NCT02936687",
      "title": "Mechanisms of Cerebrovascular Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "NOS Inhibition",
          "type": "DRUG"
        },
        {
          "name": "ET-1 Inhibition",
          "type": "DRUG"
        },
        {
          "name": "NOS Inhibition Placebo",
          "type": "DRUG"
        },
        {
          "name": "3 Tesla MRI",
          "type": "DEVICE"
        },
        {
          "name": "Intravenous Catheter",
          "type": "DEVICE"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "ET-1 Inhibition Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-01-31",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936687"
    },
    {
      "nct_id": "NCT00046501",
      "title": "Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Lantus (insulin glargine [rDNA origin] injection)",
          "type": "DRUG"
        },
        {
          "name": "Humulin N",
          "type": "DRUG"
        },
        {
          "name": "Humulin L",
          "type": "DRUG"
        },
        {
          "name": "Lispro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "9 Years to 17 Years"
      },
      "enrollment_count": 250,
      "start_date": "2002-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-09-05T06:19:07.015Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046501"
    }
  ]
}